PAA 4.00% 24.0¢ pharmaust limited

This may appear to be a disappointment but it could also be a...

  1. 260 Posts.
    lightbulb Created with Sketch. 337
    This may appear to be a disappointment but it could also be a blessing in disguise.

    It is a business reality that Australian goods and services are undercut by cheaper overseas labour and production capabilities. Unfortunately Australia has slowly become the "Can't Do" nation over the past generations. We are incapable of having a local car manufacturing industry, we are incapable of recycling our own plastic waste, we sell off our resources.

    Epichem is merely the latest victim of globalism.

    The company focus is now 100% concentrated on generating a valuable commercial outcome for Monepantel in three key areas - Canine Lymphoma, Human MND and Human Cancer. I believe that anti-viral properties may also be in the mix, but I think Covid is a no-go zone.

    There will be a clear mission for the new CEO and the BoD - to "Make It Happen".

    On balance, I'm still confident in the value of MPL and the possibilities of a successful commercial outcome are increasing with every clinical trial result.

    All in my own opinion. Keep the Faith.
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.010(4.00%)
Mkt cap ! $94.80M
Open High Low Value Volume
25.0¢ 25.0¢ 23.5¢ $140.9K 586.1K

Buyers (Bids)

No. Vol. Price($)
2 12010 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 70000 1
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
23.5¢
  Change
-0.010 ( 4.08 %)
Open High Low Volume
24.0¢ 24.5¢ 23.5¢ 164909
Last updated 15.58pm 26/04/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.